{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,4]],"date-time":"2026-06-04T16:21:35Z","timestamp":1780590095967,"version":"3.54.1"},"reference-count":32,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"5","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,5]]},"abstract":"<jats:sec>\n                    <jats:title>Objectives:<\/jats:title>\n                    <jats:p>\n                      <jats:italic toggle=\"yes\">Mycoplasma pneumoniae<\/jats:italic>\n                      (MP) is a prevalent bacterial respiratory pathogen known for cyclic epidemics every 3\u20135 years, potentially linked to waning immunity. Following the global decline post-coronavirus disease 2019, MP has re-emerged since late 2023. Given the extended interval since the last epidemic, we compared pediatric MP\u2019s clinical presentation and outcomes during the recent and previous outbreaks spanning 17 years at a tertiary center in Jerusalem, Israel.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>We conducted a retrospective cohort study at Hadassah Medical Center, analyzing demographic, clinical and treatment data from pediatric patients (0\u201317 years) with PCR-confirmed MP. In 2024, daily reports updated physicians on positive cases. We compared 2024 data (221 patients) with cohorts from 2007 to 2017 (352 patients) and initial epidemic years (2012, 2015; 139 patients).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>\n                      The 2024 epidemic showed an increased median age (8.0 vs. 5.8 years;\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      = 0.0002), higher female prevalence (56% vs. 44%;\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      = 0.007), and altered clinical manifestations: increased cough (78% vs. 63%;\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      = 0.0002), fever (79% vs. 64%;\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      = 0.0004), consolidation on radiograph (48% vs. 39%;\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      = 0.0244) and pleural effusions (5% vs. 0%;\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      &lt; 0.0001). Rash incidence decreased (8% vs. 16%;\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      = 0.0031). Significant differences in age, sex, pleural effusions and rash persisted when comparing initial epidemic years. Early emergency department diagnosis rose in 2024 from 43% to 80%. The hospitalization rate decreased from 70% to 30% and was overall lower than 2007\u20132017 (81%;\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      &lt; 0.001).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions:<\/jats:title>\n                    <jats:p>Pediatric MP presentation in 2024 differed notably from prior epidemics, marked by increased severe pneumonia in older children. Enhanced awareness facilitated rapid diagnostics, reducing hospital admissions, unnecessary tests and inappropriate antibiotic use.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1097\/inf.0000000000005070","type":"journal-article","created":{"date-parts":[[2025,12,9]],"date-time":"2025-12-09T16:00:56Z","timestamp":1765296056000},"page":"405-410","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":1,"title":["Clinical Presentation of Pediatric Mycoplasma pneumoniae Before and After the COVID-19 Pandemic"],"prefix":"10.1097","volume":"45","author":[{"given":"Tehila","family":"Haltovsky","sequence":"first","affiliation":[{"name":"Department of Pediatrics"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Itai","family":"Gross","sequence":"additional","affiliation":[{"name":"Pediatric Emergency Department, Faculty of Medicine"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yair","family":"Weiss","sequence":"additional","affiliation":[{"name":"Faculty of Medicine"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ayelet","family":"Michael-Gayego","sequence":"additional","affiliation":[{"name":"Department of Clinical Microbiology and Infectious Diseases"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ran","family":"Nir-Paz","sequence":"additional","affiliation":[{"name":"Department of Clinical Microbiology and Infectious Diseases"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3159-8426","authenticated-orcid":false,"given":"Oren","family":"Gordon","sequence":"additional","affiliation":[{"name":"Pediatric Infectious Diseases Unit and Goldyne Savad Institute of Gene Therapy, Hadassah Medical Center, Jerusalem, Israel."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saar","family":"Hashavya","sequence":"additional","affiliation":[{"name":"Pediatric Emergency Department, Faculty of Medicine"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2025,11,25]]},"reference":[{"key":"R1-20260410","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1097\/INF.0000000000000171","article-title":"Mycoplasma pneumoniae infections in childhood.","volume":"33","author":"Atkinson","year":"2014","journal-title":"Pediatr Infect Dis J"},{"key":"R2-20260410","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1056\/NEJMoa1500245","article-title":"Community-acquired pneumonia requiring hospitalization among U.S. adults.","volume":"373","author":"Jain","year":"2015","journal-title":"N Engl J Med"},{"key":"R3-20260410","first-page":"117","article-title":"The prevalence of Mycoplasma pneumoniae in ambulatory patients with nonstreptococcal sore throat.","volume":"23","author":"Williams","year":"1991","journal-title":"Fam Med"},{"key":"R4-20260410","doi-asserted-by":"crossref","first-page":"e02008-16","DOI":"10.1128\/AAC.02008-16","article-title":"In vitro activities of lefamulin and other antimicrobial agents against macrolide-susceptible and macrolide-resistant Mycoplasma pneumoniae from the United States, Europe, and China.","volume":"61","author":"Waites","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"key":"R5-20260410","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1128\/CMR.00114-16","article-title":"Mycoplasma pneumoniae from the respiratory tract and beyond.","volume":"30","author":"Waites","year":"2017","journal-title":"Clin Microbiol Rev"},{"key":"R6-20260410","doi-asserted-by":"crossref","first-page":"19865","DOI":"10.2807\/ese.16.19.19865-en","article-title":"Increased incidence of Mycoplasma pneumoniae infection in England and Wales in 2010: multilocus variable number tandem repeat analysis typing and macrolide susceptibility.","volume":"16","author":"Chalker","year":"2011","journal-title":"Euro Surveill"},{"key":"R7-20260410","doi-asserted-by":"crossref","first-page":"1900112","DOI":"10.2807\/1560-7917.ES.2020.25.2.1900112","article-title":"Mycoplasma pneumoniae infections, 11 countries in Europe and Israel, 2011 to 2016.","volume":"25","author":"Beeton","year":"2020","journal-title":"Euro Surveill"},{"key":"R8-20260410","doi-asserted-by":"crossref","first-page":"101019","DOI":"10.1016\/j.lanmic.2024.101019","article-title":"Global spatiotemporal dynamics of Mycoplasma pneumoniae re-emergence after COVID-19 pandemic restrictions: an epidemiological and transmission modelling study.","volume":"6","year":"2025","journal-title":"Lancet Microbe"},{"key":"R9-20260410","doi-asserted-by":"crossref","first-page":"100808","DOI":"10.1016\/j.epidem.2024.100808","article-title":"Predicting the impact of non-pharmaceutical interventions against COVID-19 on Mycoplasma pneumoniae in the United States.","volume":"49","author":"Park","year":"2024","journal-title":"Epidemics"},{"key":"R10-20260410","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1093\/jpids\/piae011","article-title":"Mycoplasma pneumoniae in Colombian pediatric patients post-pandemic.","volume":"13","author":"Gutierrez-Tobar","year":"2024","journal-title":"J. Pediatric Infect. Dis. Soc"},{"key":"R11-20260410","doi-asserted-by":"crossref","first-page":"166","DOI":"10.3390\/microorganisms11010166","article-title":"Viral and bacterial respiratory pathogens during the COVID-19 pandemic in Israel.","volume":"11","author":"Oster","year":"2023","journal-title":"Microorganisms"},{"key":"R12-20260410","doi-asserted-by":"crossref","first-page":"101103","DOI":"10.1016\/j.lanepe.2024.101103","article-title":"Mycoplasma pneumoniae incidence, phenotype, and severity in children and adolescents in Denmark before, during, and after the COVID-19 pandemic: a nationwide multicentre population-based cohort study.","volume":"47","author":"Dungu","year":"2024","journal-title":"Lancet Reg Health Eur"},{"key":"R13-20260410","doi-asserted-by":"crossref","first-page":"149","DOI":"10.15585\/mmwr.mm7307a3","article-title":"Notes from the field: reemergence of Mycoplasma pneumoniae infections in children and adolescents after the COVID-19 pandemic, United States, 2018-2024.","volume":"73","author":"Edens","year":"2024","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"R14-20260410","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1097\/INF.0000000000004461","article-title":"Increased severity of Mycoplasma pneumoniae infections in Spanish children.","volume":"43","author":"Mendez-Echevarria","year":"2024","journal-title":"Pediatr Infect Dis J"},{"key":"R15-20260410","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1016\/j.cmi.2024.03.008","article-title":"Unexpected increase of severe Mycoplasma pneumoniae pneumonia in adults in Southern Switzerland.","volume":"30","author":"Garzoni","year":"2024","journal-title":"Clin Microbiol Infect"},{"key":"R16-20260410","doi-asserted-by":"crossref","first-page":"1449511","DOI":"10.3389\/fmicb.2024.1449511","article-title":"Increased macrolide resistance rate of Mycoplasma pneumoniae correlated with epidemic in Beijing, China in 2023.","volume":"15","author":"Chen","year":"2024","journal-title":"Front Microbiol"},{"key":"R17-20260410","doi-asserted-by":"crossref","first-page":"698","DOI":"10.1097\/INF.0000000000002291","article-title":"The clinical presentation of pediatric Mycoplasma pneumoniae infections\u2014a single center cohort.","volume":"38","author":"Gordon","year":"2019","journal-title":"Pediatr Infect Dis J"},{"key":"R18-20260410","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.3201\/eid1706.101558","article-title":"Macrolide resistance in Mycoplasma pneumoniae, Israel, 2010.","volume":"17","author":"Averbuch","year":"2011","journal-title":"Emerg Infect Dis"},{"key":"R19-20260410","doi-asserted-by":"crossref","first-page":"4078","DOI":"10.1128\/JCM.02048-14","article-title":"Evaluation of five real-time PCR assays for detection of Mycoplasma pneumoniae.","volume":"52","author":"Dumke","year":"2014","journal-title":"J Clin Microbiol"},{"key":"R20-20260410","doi-asserted-by":"crossref","first-page":"394","DOI":"10.15585\/mmwr.mm7423a1","article-title":"Mycoplasma pneumoniae infections in hospitalized children\u2014United States, 2018-2024.","volume":"74","author":"Diaz","year":"2025","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"R21-20260410","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1093\/cid\/ciy419","article-title":"Mycoplasma pneumoniae among children hospitalized with community-acquired pneumonia.","volume":"68","author":"Kutty","year":"2019","journal-title":"Clin Infect Dis"},{"key":"R22-20260410","doi-asserted-by":"crossref","first-page":"601","DOI":"10.3109\/00365548809035660","article-title":"Detection of specific IgM antibodies for the diagnosis of Mycoplasma pneumoniae infections: a clinical evaluation.","volume":"20","author":"Vikerfors","year":"1988","journal-title":"Scand J Infect Dis"},{"key":"R23-20260410","first-page":"CD004875","article-title":"Antibiotics for community-acquired lower respiratory tract infections secondary to Mycoplasma pneumoniae in children.","volume":"1","author":"Gardiner","year":"2015","journal-title":"Cochrane Database Syst Rev"},{"key":"R24-20260410","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1080\/14787210.2018.1414599","article-title":"Antimicrobial therapy of macrolide-resistant Mycoplasma pneumoniae pneumonia in children.","volume":"16","author":"Lee","year":"2018","journal-title":"Expert Rev Anti Infect Ther"},{"key":"R25-20260410","doi-asserted-by":"crossref","first-page":"1184","DOI":"10.1001\/jamapediatrics.2017.3225","article-title":"Effectiveness of beta-lactam monotherapy vs macrolide combination therapy for children hospitalized with pneumonia.","volume":"171","author":"Williams","year":"2017","journal-title":"JAMA Pediatr"},{"key":"R26-20260410","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1186\/s13063-024-08438-6","article-title":"A randomized controlled non-inferiority trial of placebo versus macrolide antibiotics for Mycoplasma pneumoniae infection in children with community-acquired pneumonia: trial protocol for the MYTHIC study.","volume":"25","author":"Meyer Sauteur","year":"2024","journal-title":"Trials"},{"key":"R27-20260410","doi-asserted-by":"crossref","first-page":"696","DOI":"10.1097\/PEC.0b013e3182948f11","article-title":"Impact of the availability of an influenza virus rapid antigen test on diagnostic decision making in a pediatric emergency department.","volume":"29","author":"Hojat","year":"2013","journal-title":"Pediatr Emerg Care"},{"key":"R28-20260410","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1097\/00006454-200004000-00008","article-title":"Effect of rapid diagnosis on management of influenza A infections.","volume":"19","author":"Noyola","year":"2000","journal-title":"Pediatr Infect Dis J"},{"key":"R29-20260410","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1001\/archpedi.160.7.713","article-title":"Accuracy and impact of a point-of-care rapid influenza test in young children with respiratory illnesses.","volume":"160","author":"Poehling","year":"2006","journal-title":"Arch Pediatr Adolesc Med"},{"key":"R30-20260410","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1001\/archpedi.156.1.41","article-title":"Effect of rapid diagnosis of influenza virus type A on the emergency department management of febrile infants and toddlers.","volume":"156","author":"Sharma","year":"2002","journal-title":"Arch Pediatr Adolesc Med"},{"key":"R31-20260410","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1542\/peds.112.2.363","article-title":"Impact of the rapid diagnosis of influenza on physician decision-making and patient management in the pediatric emergency department: results of a randomized, prospective, controlled trial.","volume":"112","author":"Bonner","year":"2003","journal-title":"Pediatrics"},{"key":"R32-20260410","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1016\/j.jiac.2015.02.007","article-title":"Diagnostic sensitivity of a rapid antigen test for the detection of Mycoplasma pneumoniae: comparison with real-time PCR.","volume":"21","author":"Miyashita","year":"2015","journal-title":"J Infect Chemother"}],"container-title":["Pediatric Infectious Disease Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/INF.0000000000005070","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,10]],"date-time":"2026-04-10T04:00:49Z","timestamp":1775793649000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/INF.0000000000005070"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,25]]},"references-count":32,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.1097\/inf.0000000000005070","relation":{},"ISSN":["0891-3668","1532-0987"],"issn-type":[{"value":"0891-3668","type":"print"},{"value":"1532-0987","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,25]]}}}